儿童复发急性髓系白血病强化再诱导治疗及异基因干细胞移植后的结局
1993至2012年北欧543名儿童按两项连续方案治疗,208例复发;146例(70%)达第二次完全缓解,再诱导治疗者5年总生存率43±4%,复发后行干细胞移植巩固者5年总生存率61±5%。
要点
- 复发后第二次完全缓解率达70%(146/208)。
- 再诱导治疗者5年总生存率为43±4%。
- 复发后行干细胞移植巩固者5年总生存率为61±5%。
核心结论
- 强化再诱导治疗后行干细胞移植可使复发急性髓系白血病儿童获得40%的治愈率。
研究设计与样本
- 1993至2012年北欧543名儿童按两项连续方案治疗,其中208例复发,分析疾病特征、一线治疗、复发治疗及首次缓解持续时间对结局的影响。
主要发现
- 146例(70%)患者达到第二次完全缓解。
- 全组估计5年总生存率为39±4%,接受再诱导治疗的190例患者为43±4%。
- 再诱导方案中76%含氟达拉滨、阿糖胞苷(FLA)±蒽环类,18%为北欧儿科血液肿瘤学会(NOPHO)前期 блок方案,5%为其他方案。
- 诊断后≥1年晚期复发、首次缓解未行异基因干细胞移植及核心结合因子急性髓系白血病为生存的独立有利预后因素。
- 复发后接受干细胞移植巩固的128例儿童(124例处于第二次完全缓解)5年总生存率为61±5%。
关键数值与推荐
- 再诱导治疗方案:76%含氟达拉滨、阿糖胞苷(FLA)±蒽环类,18%为NOPHO前期 блок方案,5%为其他方案。
- 独立有利预后因素:晚期复发≥1年、首次缓解未行异基因干细胞移植、核心结合因子急性髓系白血病。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Given that 30-40% of children with acute myeloid leukaemia (AML) relapse after primary therapy it is important to define prognostic factors and identify optimal therapy. From 1993 to 2012, 543 children from the Nordic countries were treated according to two consecutive protocols: 208 children relapsed. The influence of disease characteristics, first line treatment, relapse therapy and duration of first remission on outcome was analysed. Second complete remission (CR2) was achieved in 146 (70%) patients. Estimated 5-year overall survival (OS5y ) was 39 ± 4% for the whole group and 43 ± 4% for the 190 patients given re-induction therapy, of whom 76% received regimens that included fludarabine, cytarabine (FLA) ± anthracyclines, 18% received Nordic Society for Paediatric Haematology and Oncology (NOPHO) upfront blocks and 5% received other regimens. Late relapse ≥1 year from diagnosis, no allogeneic stem cell transplantation (SCT) in first remission and core binding factor AML were independent favourable prognostic factors for survival. For the 128 children (124 in CR2) that received SCT as consolidation therapy after relapse, OS5y was 61 ± 5%. Four of 19 children (21%) survived without receiving SCT as part of relapse therapy. Our data show that intensive re-induction followed by SCT can give cure rates of 40% in children with relapsed AML.
引用
- Karlsson L, Forestier E, Hasle H, et al. Outcome after intensive reinduction therapy and allogeneic stem cell transplant in paediatric relapsed acute myeloid leukaemia. Br J Haematol. 2017. PMID: 28439893. doi:10.1111/bjh.14720
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。